BIOLASE, Inc. (BIOL) reported a series of moves with the plan of strengthening the firm's leadership, global competitiveness and the focus on its professional customers and their patients.
With the decisive confirmation from the Delaware Supreme Court on June 12, 2014, of the Delaware Chancery Court's May 21, 2014 ruling, the board has been established as Paul Clark, Fred Moll, Norman Nemoy, Federico Pignatelli, and Jim Talevich. Today, the board added Jeffrey Nugent as the sixth member.
Following the Delaware Supreme Court's ruling, on June 12, 2014 Pignatelli resigned as Chairman and Chief Executive.
Today, the board elected Clark as Board Chairman, who has served as Chairman, CEO, and President of ICOS Corp., which was acquired by Lilly in 2007. Previously, he was the President of Abbott's Pharmaceuticals Division. Meanwhile, Nugent has accepted the interim CEO post, whilst a formal search is initiated to name a permanent CEO.
For comments and feedback contact: editorial@rttnews.com
Business News